Last reviewed 2026-04-22 · How we verify

CT-P44(Daratumumab)

CT-P44 is a monoclonal antibody that binds to CD38 on multiple myeloma cells, triggering their destruction through antibody-dependent cellular cytotoxicity and direct apoptosis.

CT-P44 is a monoclonal antibody that binds to CD38 on multiple myeloma cells, triggering their destruction through antibody-dependent cellular cytotoxicity and direct apoptosis. Used for Multiple myeloma (in combination with standard therapies), Relapsed or refractory multiple myeloma.

At a glance

Mechanism of action

As a CD38-targeting monoclonal antibody, CT-P44 (daratumumab biosimilar) engages the immune system to eliminate CD38-expressing plasma cells in multiple myeloma. It works through multiple mechanisms including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), as well as direct induction of apoptosis in myeloma cells.

Approved indications

• Multiple myeloma (in combination with standard therapies)
• Relapsed or refractory multiple myeloma

Common side effects

• Infusion-related reactions
• Neutropenia
• Anemia
• Thrombocytopenia
• Fatigue
• Upper respiratory tract infection

Key clinical trials

• A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.